1-20 of 35
Myo Htut
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Clinical Trials & Observations
Surbhi Sidana, Krina K. Patel, Lauren C Peres, Radhika Bansal, Mehmet Hakan Kocoglu, Leyla Shune, Shebli Atrash, Kinaya Smith, Shonali Midha, Christopher J Ferreri, Binod Dhakal, Danai Dima, Patrick Costello, Charlotte Wagner, Ran Reshef, Hitomi Hosoya, Lekha Mikkilineni, Djordje Atanackovic, Saurabh Chhabra, Ricardo D Parrondo, Omar Nadeem, Hashim Mann, Nilesh Kalariya, Vanna Hovanky, Gabriel DeAvila, Ciara L Freeman, Frederick L Locke, Melissa Alsina, Sandy Wong, Megan M Herr, Myo Htut, Joseph P. McGuirk, Douglas W Sborov, Jack Khouri, Thomas Martin, Murali Janakiram, Yi Lin, Doris K Hansen
Journal: Blood
Blood blood.2024025945.
https://doi.org/10.1182/blood.2024025945
Published: 2024
Includes: Supplemental data
Journal Articles

Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Scott R. Goldsmith, Geoffrey P. Shouse, F. Lennie Wong, Alysia Bosworth, Aleksi Iujuridze, Sitong Chen, June-Wha Rhee, Matthew G. Mei, Murali Janakiram, Myo Htut, Stephen J. Forman, Raju Pillai, L. Elizabeth Budde, Saro Armenian
Journal: Blood
Blood (2023) 142 (Supplement 1): 4814.
https://doi.org/10.1182/blood-2023-185157
Published: 2023
Journal Articles

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Lawrence Liu, Scott R. Goldsmith, Sheryl Leahey, Carlos Gomez Luna, Shawn Streeter, Adam Braun, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Azra Borogovac, Jonathan Keats, Myo Htut, Arnab Chowdhury, Sanjeet Singh Dadwal, Amrita Krishnan, Murali Janakiram
Journal: Blood
Blood (2023) 142 (Supplement 1): 1987.
https://doi.org/10.1182/blood-2023-188077
Published: 2023
Journal Articles

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Susan Bal, Myo Htut, Omar Nadeem, Larry D. Anderson, Jr., Hakan Koçoğlu, Tara Gregory, Adriana C Rossi, Tom Martin, Daniel N. Egan, Luciano Costa, Hongxiang Hu, Yanping Chen, Shaoyi Li, Lisa M. Kelly, Naomey Sarkis, Safiyyah Ziyad, Wei-Ming Kao, Allison June Kaeding, Michael R. Burgess, Jésus G Berdeja
Journal: Blood
Blood (2023) 142 (Supplement 1): 219.
https://doi.org/10.1182/blood-2023-181857
Published: 2023
Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Shonali Midha, Ashwath Gurumurthi, Patrick Costello, Robert A. Redd, Ciara Louise L. Freeman, Omar Castaneda, Rebecca Gonzalez, Filip Ionescu, Mahmoud Gaballa, Nilesh Kalariya, Jack Khouri, Danai Dima, Mehmet H. Kocoglu, Douglas Sborov, Charlotte B Wagner, Shebli Atrash, Peter M. Voorhees, Hamza Hashmi, James A Davis, Peter A. Forsberg, Joseph P McGuirk, Leyla Shune, Megan Herr, Ran Reshef, Yi Lin, Myo Htut, Thomas Martin, Surbhi Sidana, Doris K. Hansen, Omar Nadeem, Krina K. Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3499.
https://doi.org/10.1182/blood-2023-187565
Published: 2023
Journal Articles

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, M. Hakan Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Jr., Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison J. Kaeding, Michael R. Burgess, Kristen Hege, Jesus Berdeja
Journal: Blood
Blood (2022) 140 (Supplement 1): 883–885.
https://doi.org/10.1182/blood-2022-162395
Published: 2022
Journal Articles

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Jeffrey V. Matous, Michaela Liedtke, Surbhi Sidana, Olalekan O. Oluwole, Meera Mohan, Jose C. Cruz, Rajneesh Nath, Faiz Anwer, Adriana Rossi, Myo Htut, Shahbaz A. Malik, Srinivas Ghatta, Myles Dillon, Wendy Ying, Lynn Navale, Erin E. Karski, Arun Balakumaran, Shaji K. Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 4620–4622.
https://doi.org/10.1182/blood-2022-158231
Published: 2022
Journal Articles

Phase 1/2 Study of Nexi-002 Autologous Multi-Antigen-Specific CD8+ T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma

Robert D Knight, Myo Htut, Juan C. Varela, Andrew Kin, Vineetha Edavana, Emily Lu, Sojung Kim, Lauren Suarez, Mathias Oelke, Daniel Bednarik
Journal: Blood
Blood (2021) 138 (Supplement 1): 2824.
https://doi.org/10.1182/blood-2021-152185
Published: 2021
Journal Articles

Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

Thomas Martin, Saad Z. Usmani, Jesús G. Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Deepu Madduri, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Yi Lin, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 549.
https://doi.org/10.1182/blood-2021-146060
Published: 2021
Journal Articles

Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience

Idoroenyi Amanam, Janny M. Yao, Alfredo Puing, Ni-Chun Tsai, Diana Samuels, Dat Ngo, Stephanie Ho, Haris Ali, Ahmed Aribi, Shukaib Arslan, Andrew S. Artz, Myo Htut, Paul Koller, Amandeep Salhotra, Karamjeet S. Sandhu, Liana Nikolaenko, Anna B Pawlowska, Geoffrey Shouse, Anthony S. Stein, Guido Marcucci, Stephen J Forman, Ryotaro Nakamura, Sanjeet S Dadwal, Monzr M. Al Malki
Journal: Blood
Blood (2021) 138 (Supplement 1): 3037.
https://doi.org/10.1182/blood-2021-154187
Published: 2021
Journal Articles

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, Michaela Liedtke, Surbhi Sidana, Jeffrey V. Matous, Saurabh Chhabra, Olalekan O. Oluwole, Shahbaz A. Malik, Shaji Kumar, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Sundar Jagannath, Myo Htut, Noopur S. Raje, David S. Siegel, Erin E. Karski, Wade Lovelace, Afrodite Lourbakos, Srinand Ponnathapura Nandakumar, Arun Balakumaran, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 651.
https://doi.org/10.1182/blood-2021-145572
Published: 2021
Journal Articles

A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation

Karamjeet S. Sandhu, Dongyun Yang, Sally Mokhtari, Sanjeet S Dadwal, Vinod A. Pullarkat, Monzr M. Al Malki, Thai Cao, Ricardo Spielberger, Amandeep Salhotra, Haris Ali, Andrew S. Artz, Anthony S. Stein, Myo Htut, Elizabeth Budde, Leslie L. Popplewell, Harry Xu, Lauren Reining, Lucy Y Ghoda, Ibrahim Aldoss, Guido Marcucci, Stephen J Forman, Sarah Highlander, Ryotaro Nakamura
Journal: Blood
Blood (2021) 138 (Supplement 1): 334.
https://doi.org/10.1182/blood-2021-153821
Published: 2021
Journal Articles

Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Thomas Martin, III, MD, Yi Lin, MD PhD, Mounzer Agha, MD, Adam D. Cohen, MD, Myo Htut, MD, A. Keith Stewart, MBChB, Parameswaran Hari, MD MRCP, Jesus G. Berdeja, MD, Deepu Madduri, MD, Saad Z. Usmani, MDMBBS,MBA, Tzu-Min Yeh, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, William Deraedt, MSc, Katharine S. Gries, PhD PharmD, John Fastenau, RPh, MPH, PhD, Xiaoling Wu, PhD, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Andrzej Jakubowiak, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-136368
Published: 2020
Journal Articles

Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Parameswaran Hari, MD MRCP, Myo Htut, MD, Jesus G. Berdeja, MD, Deepu Madduri, MD, Saad Z. Usmani, MDMBBS,MBA, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, Katharine S. Gries, PhD PharmD, John Fastenau, RPh, MPH, PhD, William Deraedt, MSc, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Sigrid Crawford, MA, Ross Morrison, MPH, Lynda Doward, MRes, Andrzej Jakubowiak, MD PhD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–15.
https://doi.org/10.1182/blood-2020-136383
Published: 2020
Journal Articles

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Deepu Madduri, MD, Jesus G. Berdeja, MD, Saad Z. Usmani, MDMBBS,MBA, Andrzej Jakubowiak, MD PhD, Mounzer Agha, MD, Adam D. Cohen, MD, A. Keith Stewart, MBChB, Parameswaran Hari, MD MRCP, Myo Htut, MD, Elizabeth O'Donnell, MD, Nikhil C. Munshi, MD, David E. Avigan, MD, Abhinav Deol, MD, Alexander M. Lesokhin, MD, Indrajeet Singh, PhD, Enrique Zudaire, PhD, Tzu-Min Yeh, Alicia J. Allred, PhD, Yunsi Olyslager, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M. Schecter, MD, Carolyn C. Jackson, MD MPH, William Deraedt, MSc, Sen Hong Zhuang, MD PhD, Jeffrey R. Infante, MD, Dong Geng, PhD, Xiaoling Wu, PhD, Marlene J. Carrasco, MD PhD MPH, Muhammad Akram, MD, Farah Hossain, PharmD, Syed Rizvi, MD, Frank Fan, MD PhD, Sundar Jagannath, MD, Yi Lin, MD PhD, Thomas Martin, III, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–25.
https://doi.org/10.1182/blood-2020-136307
Published: 2020
Journal Articles

Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

Karthik Ramasamy, Ajay Nooka, MDMPH, Hang Quach, MDFRACP,FRCPA,MBBS, Myo Htut, MD, Rakesh Popat, Michaela Liedtke, MD, Sascha A Tuchman, MD, Jacob P. Laubach, MD, Cristina Gasparetto, MD, Asher A. Chanan-Khan, MD, Mark Hertzberg, MBBS PhDFRACP FRCPA, Mark Demario, MD MPH, Eveline Nueesch, PhD, Evelyne Chesne, PhD, Izolda Franjkovic, PhD, Katharina Lechner, Martin Kornacker, MD, Hearn Jay Cho, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–14.
https://doi.org/10.1182/blood-2020-136392
Published: 2020
Journal Articles

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey A. Zonder, Thomas G. Martin, III, MD, Janice Chen, PhD, Christopher Brooks, PhD, Peter McDonald, Nicole Rupprecht, Halyna Wysowskyj, Dharminder Chauhan, PhD, Arghya Ray, PhD, Kenneth C. Anderson, MD, Claudia E. Paba-Prada, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3145.
https://doi.org/10.1182/blood-2019-130410
Published: 2019
Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

Michael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, MD, Flavia Pichiorri, PhD, Firoozeh Sahebi, Tim Synold, Xiwei Wu, James F Sanchez, Amrita Krishnan, MD, Stephen J Forman, Steven T Rosen
Journal: Blood
Blood (2018) 132 (Supplement 1): 2007.
https://doi.org/10.1182/blood-2018-99-120042
Published: 2018
Journal Articles

CD84: A Potential Novel Therapeutic Target in Multiple Myeloma

Emine Gulsen Gunes, PhD, Hadas Lewinsky, Domenico Viola, Enrico Caserta, Michael Rosenzweig, Myo Htut, James F Sanchez, PhD, Ralf Buettner, PhD, Guido Marcucci, Jonathan J Keats, PhD, Amrita Krishnan, MD, Steven T Rosen, Idit Shachar, Flavia Pichiorri, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1924.
https://doi.org/10.1182/blood-2018-99-119655
Published: 2018
Journal Articles

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody, MBBS, Myo Htut, MD, Kelvin P. Lee, MD, William Bensinger, MD, Todd Devries, PhD, Julia Piasecki, BA, Safiyyah Ziyad, PhD, Michelle Blake, PhD, John Byon, MDPhD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 957.
https://doi.org/10.1182/blood-2018-99-113548
Published: 2018